02209nas a2200349   4500000000100000008004100001260001300042653001500055653001000070653002600080653002700106653002400133653003800157653001100195653001100206653001200217653000900229653001600238653002500254653001700279653003000296653000900326100001400335700001600349700001600365245011000381856004100491300001200532490000700544520129400551022001401845       1991                            d  c1991 Sep10aAdolescent10aAdult10aAntibodies, Bacterial10aAntibodies, Monoclonal10aAntigens, Bacterial10aEnzyme-Linked Immunosorbent Assay10aFemale10aHumans10aleprosy10aMale10aMiddle Aged10aMycobacterium leprae10aNasal Mucosa10aPredictive Value of Tests10aSkin1 aSingh N B1 aChoudhary A1 aBhatnagar S00aDetection of M. leprae-specific antigens with dot-ELISA in urine and nasal samples from leprosy patients.  uhttp://ila.ilsl.br/pdfs/v59n3a03.pdf  a398-4040 v593 a<p>One-hundred-two urine and nasal samples collected from leprosy patients of different classifications of disease were studied for the presence of Mycobacterium leprae antigens, including phenolic glycolipid-I (PGL-I). Lipids were extracted from the urine samples, and nasal washings were concentrated and used as such in the dot-ELISA. Two types of primary antibodies, a polyclonal antibody obtained from lepromatous (LL) leprosy patients' pooled and absorbed sera and an anti-PGL-I monoclonal antibody, were used for the detection of M. leprae antigens from these samples. The polyclonal sera detected 23% to 36% of the paucibacillary (PB) and 100% of the multibacillary (MB) leprosy cases from the urine samples. Corresponding values for nasal detection were 10% to 18% for PB and 100% for MB cases. The monoclonal antibody against PGL-I could not detect tuberculoid (TT) leprosy cases. From the urine samples, however, 16% of the borderline tuberculoid (BT), 25% of the borderline (BB), 80% of the borderline lepromatous (BL), and 100% of the LL leprosy cases were detectable. It was interesting to note that PB, skin-smear negative cases were detectable from urine examination. The specificity and sensitivity of the test is discussed in relation to the crossreacting antigens.</p>
  a0148-916X